Treatment Inertia in Patients With Familial Hypercholesterolemia

Area of Science:

• Cardiology
• Genetics
• Pharmacology

Background:

• Familial hypercholesterolemia (FH) is a genetic disorder leading to high low-density lipoprotein cholesterol (LDL-C).
• Patients with FH, especially those with existing cardiovascular disease (CVD), require effective lipid-lowering therapy.
• A care gap exists in achieving therapeutic lipid targets in FH patients.

Purpose of the Study:

• To investigate the care gap in lipid-lowering therapy for patients with familial hypercholesterolemia (FH).
• To assess treatment inertia in FH patients, including those with co-existing cardiovascular disease (CVD).
• To evaluate the effectiveness of online reminders in improving treatment adherence and achieving LDL-C targets.

Main Methods:

• Enrolled 2009 patients with cardiovascular disease (CVD) or FH and elevated LDL-C (>2.0 mmol/L) despite maximally tolerated statin therapy.
• Physicians received online reminders of treatment recommendations during follow-up.
• Compared baseline characteristics and treatment outcomes between FH and CVD patient groups.

Main Results:

• Patients with FH were younger, more likely female, non-White, and had higher baseline LDL-C compared to CVD-only patients.
• FH patients received less statin therapy at baseline (70.6% vs. 79.2%).
• Achieving LDL-C targets (≥50% reduction or <2.5 mmol/L for FH; ≤2.0 mmol/L for CVD) was suboptimal, with only 22.0% of FH-only patients reaching the primary endpoint compared to 45.8% of CVD-only patients.

Conclusions:

• Significant treatment inertia persists in patients with FH, even those with established CVD.
• Current lipid-lowering strategies are insufficient for a substantial proportion of FH patients.
• Continued education and interventions focused on FH patients are necessary to bridge the care gap and improve outcomes.